LDS/Medical Tests/Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TNFRSF1A) Gene Mutation Analysis

Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TNFRSF1A) Gene Mutation Analysis

The TNFRSF1A gene at 12p13.31 encodes for a member of the tumor necrosis factor (TNF) receptor superfamily, tumor necrosis factor receptor 1 (TNFR1). TNFR1 is present in both soluble and membrane bound forms and interacts with TNF alpha. Interaction of membrane bound TNFR1 with TNF alpha causes trimerization and activation of the receptor, which is involved in cell survival, apoptosis, and inflammation.

Mutations in the TNFRSF1A gene may result a rare syndrome called Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). Over 60 TNFRSF1A gene mutations are associated with the occurrence of TRAPS. Clinically, most patients experience fevers which recur every 5-6 weeks, abdominal pain, myositis, and rash. Less commonly vomiting, conjunctivitis, periorbital edema, headache, pharyngitis, peritonitis, pleuritis, hepatomegaly, splenomegaly and migratory erythema can be seen. Other mutations in TNFRSF1A have been associated with dysmorphic features, developmental delay, Temtamy syndrome, Perioxisome biogenesis disorder 2B, CHARGE syndrome, Tumoral calcinosis hyperphosphatemic familial 1, and other conditions including multiple sclerosis.

The pathogenic mutations in the TNFRSF1A gene are mostly missense and are clustered in exons 2, 3, 4, and 6, and in the first, second, and third cysteine-rich domains. Cysteine residue mutations, which impede the formation of disulfide bonds, have been linked to a more severe clinical picture, a higher likelihood of amyloidosis, and a higher disease penetrance than non-cysteine mutations.

  • Diagnosis of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
  • Differential diagnosis of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome from other auto-inflammatory disease
  • As an aid in diagnosis of Multiple sclerosis and other disorders

A positive result indicates the presence of mutations or pathogenic variants in TNFRSF1A gene thus suggesting TRAPS.

A negative result indicates the absence mutations or pathogenic variants in TNFRSF1A gene.

Negative for mutations analyzed (No mutation or pathogenic variant detected)

DNA sequencing, targeted variant analysis by PCR, Next generation sequencing (NGS), Sanger sequencing.

Whole blood collected in EDTA (Lavender top tube).

Stability

  • Room: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unstable
Flow cytometric analysis of TNF-R1 expression, plasma TNF-R1 concentration.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login